Tin tức & Cập nhật
Xem bài viết Da liễu
Xem
Chỉ hiển thị Multimedia

Bimekizumab safe, effective in moderate-to-severe plaque psoriasis
18 Sep 2023
bởiStephen Padilla
The high clinical response levels achieved with bimekizumab over 48 weeks persist up to week 96 in patients with moderate-to-severe plaque psoriasis, results of the BE RADIANT phase IIIb trial have shown. In addition, those on secukinumab who switched to bimekizumab have achieved similar responses at 96 weeks.
18 Sep 2023








